Call Options

9 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.85 - $5.05 $112,805 - $147,965
29,300 Added 263.96%
40,400 $190,000
Q2 2024

Aug 14, 2024

SELL
$3.6 - $5.79 $105,480 - $169,647
-29,300 Reduced 72.52%
11,100 $42,000
Q1 2024

May 15, 2024

BUY
$3.09 - $6.0 $110,893 - $215,328
35,888 Added 795.39%
40,400 $216,000
Q4 2023

Feb 14, 2024

SELL
$1.57 - $4.58 $4,293 - $12,526
-2,735 Reduced 37.74%
4,512 $19,000
Q3 2023

Nov 14, 2023

SELL
$3.14 - $11.2 $42,390 - $151,200
-13,500 Reduced 65.07%
7,247 $28,000
Q2 2023

Aug 14, 2023

SELL
$8.45 - $12.48 $20,280 - $29,952
-2,400 Reduced 10.37%
20,747 $209,000
Q1 2023

May 15, 2023

SELL
$9.21 - $14.98 $242,508 - $394,438
-26,331 Reduced 53.22%
23,147 $236,000
Q4 2022

Feb 14, 2023

BUY
$8.57 - $17.0 $31,229 - $61,948
3,644 Added 7.95%
49,478 $463,000
Q3 2022

Nov 14, 2022

BUY
$12.56 - $17.54 $217,149 - $303,249
17,289 Added 60.57%
45,834 $667,000

Others Institutions Holding TSVT

About 2seventy bio, Inc.


  • Ticker TSVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,873,600
  • Market Cap $115M
  • Description
  • 2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a col...
More about TSVT
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.